FOXO3 Antibody

Western Blot: FOXO3 Antibody [NB100-614]

Western Blot: FOXO3 Antibody [NB100-614] - Detection of Human and Mouse FOXO3a by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.

Western Blot: FOXO3 Antibody [NB100-614]

Western Blot: FOXO3 Antibody [NB100-614] - FOXO3 Protein expression levels both control group and exercise group for skeletal muscles. Image submitted by a verified customer review *{Mouse WB}*

Immunoprecipitation: FOXO3 Antibody [NB100-614]

Immunoprecipitation: FOXO3 Antibody [NB100-614] - Detection of human FOXO3a by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from MCF-7 cells. Antibodies: Affinity purified rabbit anti-FOXO3a antibody NB100-614 used for IP at 6 ug/mg lysate. FOXO3a was also immunoprecipitated by rabbit anti-FOXO3a antibody NB100-613. For blotting immunoprecipitated FOXO3a, NB100-614 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.

Knockout Validated: FOXO3 Antibody [NB100-614]

Knockout Validated: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. Representative Western blotting results. Foxo1- or Foxo1/3-specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM-cerebellum, STR-striatum, SCD-spinal cord, CTX-cortex, BST-brain stem, MDB-midbrain, HPC-hippocampus.

Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] -

Western Blot: Rabbit Polyclonal FOXO3 Antibody [NB100-614] - Analysis of FOXO3 and FOXM1in parental HCT-116 and HCT-116-FUR cells. Image from a verified customer review.

Western Blot: FOXO3 Antibody [NB100-614] -

Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FOXO3 Antibody [NB100-614] -

Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FOXO3 Antibody [NB100-614] -

Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FOXO3 Antibody [NB100-614] -

Western Blot: FOXO3 Antibody [NB100-614] - Increased proteotoxic stress & defective autophagy in Foxo1/3/4 knockout mice. (a) Tissue lysates from 12‐month‐old WT & KO brain cortex were analyzed by WB of indicated proteins. (c) p62 IF & (d) p62 & Ub IHC on cortical neurons from 12‐month‐old WT & KO brain cortex. Red arrows point to labeling positive inclusions. Scale bar = 200 μm. (e) Quantitation of representative results for (d). (f) Indicated genotype of neural progenitor cultures was differentiated into neurons for 5 days. Some cultures were treated with rapamycin (100 ng/ml) for 24 hr on day 4 of differentiation. (h) The autophagy activity was analyzed by flow cytometry. The bar graph shows autophagy indices as % of control of (f). (i) Cultures as in (f) were treated with chloroquine (100 ng/ml) for 4 hr & analyzed for the expression levels of LC3 by WB. Representative result from three to five independent experiments is shown. (b, g, j) Quantitation of WB band densities. Only chloroquine‐treated cultures were statistically compared in (j). Error bars, mean ± SEM. *p < .05. **p < .01, ***p < .005; ****p < .001. Statistical significance was determined by one‐way ANOVA Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FOXO3 Antibody [NB100-614] -

Western Blot: FOXO3 Antibody [NB100-614] - Expression of FOXO increases in aging brain. (a) XY plots of FOXO1 or FOXO3 mRNA expression within the noted brain regions vs. age of the subjects at time of death. (b) Pearson correlation coefficients (r) & p‐values for the correlation of FOXO1 or FOXO3 mRNA expression in various regions of the human brain with the age. (c) The mRNA expressions of FOXO1 & FOXO3 were measured in human cerebellums (n = 33). Blue & green dots indicate samples used for WB in (d). The mRNA (e) & protein (f) expression of Foxo1, Foxo3, & phospho‐T24/32 Foxo1/3 in young (<3‐month, n = 6), adult (3‐18‐month, n = 6), & old (18–20‐month, n = 6) FVB/B6 mixed‐strain mouse cerebellums is shown. Each dot represents individual animal. Error bars, mean ± SEM. *p < .05; **p < .01; ***p < .005. Statistical significance was determined by unpaired t‐test. (g) FOXO1 IHC analysis of brain sections of WT & Foxo 1/3/4 KO mice. Residual FOXO1 immunoreactivity in KO mice is visible in endothelial cells (inset). Scale bar = 200 μm. (h) RT‐qPCR results for Foxo1 & Foxo3 mRNA. Empty bars represent WT, & colored bars represent KO tissues (n = 4). (i) Representative Western blotting results. Foxo1‐ or Foxo1/3‐specific knockouts (1KO or 1/3KO) selectively lost targeted isoforms. CBM—cerebellum, STR—striatum, SCD—spinal cord, CTX—cortex, BST—brain stem, MDB—midbrain, HPC—hippocampus Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29178390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.